Elevated p53 and p21waf1 mRNA expression in blood lymphocytes from lung cancer patients with chemoresistance

Cancer Detection and Prevention

Volumn 31, Issue 5, 2007, Pages 366-370

  Shih, Chuen Ming ^a   Chen, Kwunmin ^b   Wang, Yu Chieh ^b   Lee, Pei Jung ^b   Wang, Yi Ching ^b,c  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN NORMAL UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Chemoresistance; Lung cancer; Lymphocyte; p21waf1 gene; p53 gene

Indexed keywords

CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; MESSENGER RNA; PROTEIN P53;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; LUNG CANCER; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RADIATION INJURY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; ULTRAVIOLET RADIATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG RESISTANCE, NEOPLASM; GENES, P53; HUMANS; LUNG NEOPLASMS; LYMPHOCYTES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 36549020728     PISSN: 0361090X     EISSN: 15251500     Source Type: Journal    
DOI: 10.1016/j.cdp.2007.10.003     Document Type: Article

References (19)

1. Blandino G., Levine A.J., and Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18 (1999) 477-485
2. Rusch V., Klimstra D., Venkatraman E., Oliver J., Martini N., Gralla R., et al. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 55 (1995) 5038-5042
3. Zhang W., Kornblau S.M., Kobayashi T., Gambel A., Claxton D., and Deisseroth A.B. High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia. Clin Cancer Res 1 (1995) 1051-1057
4. Jung J.M., Bruner J.M., Ruan S., Langford L.A., Kyritsis A.P., Kobayashi T., et al. Increased levels of p21WAF1/Cip1 in human brain tumors. Oncogene 11 (1995) 2021-2028
5. Donato N.J., Perez M., Kang H., Siddik Z.H., Ling Y.H., and Perez-Soler R. EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity. Clin Cancer Res 6 (2000) 193-202
6. Wei Q., Xu X., Cheng L., Legerski R.J., and Ali-Osman F. Simultaneous amplification of four DNA repair genes and beta-actin in human lymphocytes by multiplex reverse transcriptase-PCR. Cancer Res 55 (1995) 5025-5029
7. Dabholkar M., Bostick-Bruton F., Weber C., Bohr V.A., Egwuagu C., and Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84 (1992) 1512-1517
8. Wang Y.C., Lee P.J., Shih C.M., Chen H.Y., Lee C.C., Chang Y.Y., et al. Damage formation and repair efficiency in the p53 gene of cell lines and blood lymphocytes assayed by multiplex long quantitative polymerase chain reaction. Anal Biochem 319 (2003) 206-215
9. Li D., Wang M., Cheng L., Spitz M.R., Hittelman W.N., and Wei Q. In vitro induction of benzo(a)pyrene diol epoxide-DNA adducts in peripheral lymphocytes as a susceptibility marker for human lung cancer. Cancer Res 56 (1996) 3638-3641
10. Marijnen C.A., Kapiteijn E., Nagtegaal I.D., Mulder-Stapel A.A., van de Velde C.J., Schrier P.I., et al. p53 expression in human rectal tissue after radiotherapy: upregulation in normal mucosa versus functional loss in rectal carcinomas. Int J Radiat Oncol Biol Phys 52 (2002) 720-728
11. Kobayashi K., and Tsukamoto I. Prolonged Jun N-terminal kinase (JNK) activation and the upregulation of p53 and p21(WAF1/CIP1) preceded apoptosis in hepatocytes after partial hepatectomy and cisplatin. Biochim Biophys Acta 1537 (2001) 79-88
12. Chen Z.P., Malapetsa A., Mohr G., Brien S., and Panasci L.C. Quantitation of ERCC-2 gene expression in human tumor cell lines by reverse transcription-polymerase chain reaction in comparison to northern blot analysis. Anal Biochem 244 (1997) 50-54
13. Wei Q., Bondy M.L., Mao L., Gaun Y., Cheng L., Cunningham J., et al. Reduced expression of mismatch repair genes measured by multiplex reverse transcription-polymerase chain reaction in human gliomas. Cancer Res 57 (1997) 1673-1677
14. Vogel U., Dybdahl M., Frentz G., and Nexo B.A. DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes. Mutat Res 461 (2000) 197-210
15. Ferry K.V., Hamilton T.C., and Johnson S.W. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol 60 (2000) 1305-1313
16. Selvakumaran M., Pisarcik D.A., Bao R., Yeung A.T., and Hamilton T.C. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 63 (2003) 1311-1316
17. MacLeod M.C. A possible role in chemical carcinogenesis for epigenetic, heritable changes in gene expression. Mol Carcinog 15 (1996) 241-250
18. Hussain S.P., and Harris C.C. Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res 58 (1998) 4023-4037
19. Roy B., Beamon J., Balint E., and Reisman D. Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors. Mol Cell Biol 14 (1994) 7805-7815